[eDisclosure Notice] KOSDAQ - 3 Days

[Asia Economy Reporter Lee Seon-ae]

◆Osstem Implant=Decision on designation as subject to delisting review by the 24th

◆Apro=Decision to dispose of treasury shares worth 800 million KRW

◆MRO=Decision on a 1-for-1 stock dividend

◆Korea Pharma=Application for Phase 2 clinical trial plan to evaluate the efficacy and safety of repeated administration of KP203 in elderly patients with sarcopenia

◆Cytogen=Notice of designation as a non-compliant disclosure corporation due to delay in disclosing change of major shareholder

◆Cass=Exercise of convertible bonds amounting to 1.52% of total issued shares

◆Enox Advanced Materials=CEO Kim Pil-young resigns

This content was produced with the assistance of AI translation services.